

Esteban Dauden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2718511/publications.pdf>

Version: 2024-02-01

113
papers

2,504
citations

218381

26
h-index

233125

45
g-index

119
all docs

119
docs citations

119
times ranked

2799
citing authors

#	ARTICLE	IF	CITATIONS
1	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1661-1669.	1.1	15
2	The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2110-2117.	1.1	4
3	Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM. <i>Actas Dermo-sifilográficas</i> , 2022, 113, 401-406.	0.2	1
4	Cutaneous vascular calcification. Peri-ecrine calcification as a diagnostic key for calciphylaxis. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 683-691.	0.7	0
5	[Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience. <i>Actas Dermo-sifilográficas</i> , 2022, 113, T401-T406.	0.2	2
6	Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: a post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1774-1783.	1.3	7
7	Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry. <i>British Journal of Dermatology</i> , 2022, 187, 817-820.	1.4	6
8	Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 431-440.	1.3	20
9	Histopathologic study of paradoxical psoriasis induced by antitumor necrosis factor alpha therapy: Is it true psoriasis?. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 813-816.	0.7	1
10	Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 513-517.	0.6	26
11	Methylation in psoriasis. Does sex matter?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e161-e163.	1.3	5
12	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	3.3	65
13	Epigenetics in Non-tumor Immune-Mediated Skin Diseases. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 137-161.	1.6	3
14	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.	1.3	5
15	Growth arrest and DNA damage-inducible proteins (GADD45) in psoriasis. <i>Scientific Reports</i> , 2021, 11, 14579.	1.6	11
16	Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents. <i>Journal of Cutaneous Pathology</i> , 2021, . . .	0.7	5
17	Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain. <i>Dermatology and Therapy</i> , 2021, 11, 2207-2215.	1.4	6
18	Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. <i>Annals of Medicine</i> , 2021, 53, 1727-1736.	1.5	4

#	ARTICLE	IF	CITATIONS
19	Psoriasis Therapy and Skin Cancer: A Review. <i>Life</i> , 2021, 11, 1109.	1.1	16
20	Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database. <i>International Journal of Dermatology</i> , 2020, 59, 197-206.	0.5	14
21	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020, 19, 102429.	2.5	197
22	Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm. <i>Actas Dermo-sifiligráficas</i> , 2020, 111, 752-760.	0.2	6
23	Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs. <i>Experimental Dermatology</i> , 2020, 29, 1225-1232.	1.4	11
24	Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e271-e275.	1.3	7
25	Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival. <i>Dermatologic Therapy</i> , 2020, 33, e14134.	0.8	12
26	Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3619-3621.e1.	2.0	7
27	Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposure and study of hypopigmentation as treatment's prognostic factor. <i>Dermatologic Therapy</i> , 2020, 33, e14428.	0.8	4
28	Pharmacogenetics Update on Biologic Therapy in Psoriasis. <i>Medicina (Lithuania)</i> , 2020, 56, 719.	0.8	11
29	Validación del método de cuantificación del área corporal afectada por la psoriasis mediante ípiz 3ptico. <i>Actas Dermo-sifiligráficas</i> , 2020, 111, 143-148.	0.2	3
30	Utility of circulating serum miRNA profiles to evaluate the potential risk and severity of immune-mediated inflammatory disorders. <i>Journal of Autoimmunity</i> , 2020, 111, 102472.	3.0	11
31	Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19. <i>British Journal of Dermatology</i> , 2020, 183, 591-593.	1.4	47
32	A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90mg. <i>Dermatologic Therapy</i> , 2020, 33, e13678.	0.8	0
33	Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement. <i>Cells</i> , 2020, 9, 1603.	1.8	10
34	Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 139-150.	0.6	37
35	Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2548-2556.	1.3	10
36	Association between eosinophilic folliculitis and follicular mucinosis. A case series. <i>International Journal of Dermatology</i> , 2020, 59, e376-e378.	0.5	3

#	ARTICLE	IF	CITATIONS
37	Reply to "Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients" To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e253-e254.	0.6	35
38	Faziales folliculärzystisches und kollagenes Hamartom: eine Variante der fibrösen Stirnplaque mit prominenter Zystenbildung?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 738-741.	0.4	0
39	Facial folliculocystic and collagen hamartoma: a variant of fibrous cephalic plaque with prominent cyst formation?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 738-741.	0.4	7
40	Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis. <i>Frontiers in Immunology</i> , 2019, 10, 1268.	2.2	18
41	Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1214-1223.	1.3	8
42	Tuberculosis re-screening in psoriatic patients under continuous biological therapy. Does the treatment modify the tuberculin skin test response?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e295-e296.	1.3	1
43	Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. <i>Reumatología Clínica</i> , 2019, 15, 63-68.	0.2	1
44	Trough (C0) and 2-hour postdose (C2) cyclosporine monitoring in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e215-e217.	1.3	0
45	Bilateral Facial Apocrine Fibrosing Hamartoma Mimicking Microcystic Adnexal Carcinoma. <i>American Journal of Dermatopathology</i> , 2019, 41, 767-770.	0.3	0
46	Psoriasis y depresión: el papel de la inflamación. <i>Actas Dermo-sifiliográficas</i> , 2019, 110, 12-19.	0.2	43
47	Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e175-e177.	1.3	13
48	Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. <i>Journal of Dermatological Treatment</i> , 2019, 30, 461-465.	1.1	27
49	GATA3 staining in primary cutaneous apocrine cribriform carcinoma: Usefulness to differentiate it from breast cancer metastasis. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 348-351.	0.7	10
50	Calcinosis cutis facial en una paciente con dermatomiositis paraneoplásica. <i>Actas Dermo-sifiliográficas</i> , 2018, 109, 760-762.	0.2	0
51	Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1887-1892.	1.3	3
52	Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 798-800.	0.6	6
53	New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. <i>Pharmacogenomics Journal</i> , 2018, 18, 70-75.	0.9	31
54	IL17RA gene variants and anti-TNF response among psoriasis patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 76-80.	0.9	28

#	ARTICLE	IF	CITATIONS
55	Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2018, 178, 798-800.	1.4	13
56	Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 209-222.	3.3	39
57	Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. <i>Pharmacogenomics</i> , 2018, 19, 7-16.	0.6	21
58	Recommendations for the management of comorbidity in hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 129-144.	1.3	43
59	Histone modifications associated with biological drug response in moderate-to-severe psoriasis. <i>Experimental Dermatology</i> , 2018, 27, 1361-1371.	1.4	48
60	Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab. <i>JAAD Case Reports</i> , 2018, 4, 842-844.	0.4	2
61	Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 584-601.	0.2	2
62	Position statement for the management of comorbidities in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2058-2073.	1.3	61
63	Serie de casos de pacientes psoriásicas expuestas a terapia biológica durante el embarazo. Registro BIOBADADERM y revisión de la literatura. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 168-170.	0.2	15
64	Mucinosis nodular asociada a gammapatía monoclonal de cadenas ligeras de significado incierto. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 272-273.	0.2	0
65	Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1271-1284.	1.3	21
66	Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. <i>Pharmacogenomics</i> , 2017, 18, 631-638.	0.6	25
67	Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1700-1708.	1.3	19
68	Prevalence of amyloid deposits determined by fine-needle aspiration of abdominal fat in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e280-e281.	1.3	0
69	No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab. <i>British Journal of Dermatology</i> , 2017, 177, 862-863.	1.4	6
70	Atypical Ulcerated Lesions in a Patient With Cogan Syndrome. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 369-371.	0.2	1
71	Inducción de anticuerpos y enfermedades autoinmunes en pacientes con psoriasis tratados con fármacos anti-TNF. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 445-456.	0.2	5
72	Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. <i>Pharmacogenomics</i> , 2017, 18, 157-164.	0.6	24

#	ARTICLE	IF	CITATIONS
73	Combination therapy of infliximab and ciclosporin in the treatment of recalcitrant psoriasis: a case series. <i>British Journal of Dermatology</i> , 2017, 176, 803-805.	1.4	1
74	European S3â€œGuideline on the systemic treatment of psoriasis vulgaris â€œ Update Apremilast and Secukinumab â€œ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1951-1963.	1.3	116
75	Topical anticholinergic drugs in the treatment of multiple hidrocystomas: a crossâ€œover, randomized, doubleâ€œblind, placeboâ€œcontrolled study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e90-e92.	1.3	2
76	Consensus document on the evaluation and treatment of moderateâ€œtoâ€œsevere psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1-18.	1.3	105
77	Eccrine porocarcinoma with extensive cutaneous metastases. <i>International Journal of Dermatology</i> , 2016, 55, e156-60.	0.5	7
78	Lymph node melanosis. Should it be managed as a highâ€œrisk melanoma? A case report and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 511-513.	1.3	2
79	Poroqueratosis pruriginosa diseminada inflamatoria. Buena respuesta a ciclosporina. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2016, 107, 261-262.	0.2	3
80	DetecciÃ³n precoz de la enfermedad psicoemocional en dermatologÃ­a. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2016, 107, 294-300.	0.2	3
81	Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis. <i>Journal of Rheumatology</i> , 2016, 43, 990-991.	1.0	3
82	Longâ€œterm treatment of neurofibromatosis 1 with ketotifen. A report of three cases. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 1092-1094.	0.7	2
83	DesmotivaciÃ³n del personal sanitario y sÃ­ndrome de burnout. Control de las situaciones de tensiÃ³n. La importancia del trabajo en equipo. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2016, 107, 400-406.	0.2	15
84	Metotrexato en psoriasis moderada-grave: revisiÃ³n de la literatura y recomendaciones de experto. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2016, 107, 194-206.	0.2	37
85	Patient-relevant needs and treatment goals in nail psoriasis. <i>Quality of Life Research</i> , 2016, 25, 1179-1188.	1.5	16
86	Paradoxical psoriasiform reactions to anti-TNFÎ± drugs are associated with genetic polymorphisms in patients with psoriasis. <i>Pharmacogenomics Journal</i> , 2016, 16, 336-340.	0.9	45
87	Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	0.9	17
88	Sweet syndrome and differentiation syndrome in a patient with acute promyelocytic leukemia. <i>World Journal of Clinical Cases</i> , 2015, 3, 196.	0.3	3
89	European S3â€œGuidelines on the systemic treatment of psoriasis vulgaris â€œ Update 2015 â€œ Short version â€œ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	1.3	353
90	ResoluciÃ³n de granuloma anular diseminado con fototerapia UVB de banda estrecha. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2015, 106, 240-241.	0.2	6

#	ARTICLE	IF	CITATIONS
91	New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: a case-control study. <i>British Journal of Dermatology</i> , 2015, 172, 1432-1435.	1.4	8
92	The polymorphism rs763780 in the <i>IL-17F</i> gene is associated with response to biological drugs in patients with psoriasis. <i>Pharmacogenomics</i> , 2015, 16, 1723-1731.	0.6	45
93	Biosimilares en dermatología. Situación actual (parte i). <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 545-549.	0.2	10
94	Análisis de la hepatotoxicidad en psoriasis tratada con ustekinumab. Estudio retrospectivo de 44 pacientes en práctica clínica habitual. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 470-476.	0.2	23
95	Biosimilares en dermatología. Situación actual (parte ii). <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 550-554.	0.2	5
96	Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 22-32.	1.3	22
97	Development and Validation of a New Instrument to Measure Health-related Quality of Life in Patients with Psoriatic Arthritis: The VITACORA-19. <i>Journal of Rheumatology</i> , 2014, 41, 2008-2017.	1.0	14
98	Impact of Active and Stable Psoriasis on Health-Related Quality of Life: The PSO-LIFE Study. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 685-693.	0.2	8
99	Pharmacogenetics of topical and systemic treatment of psoriasis. <i>Pharmacogenomics</i> , 2013, 14, 1623-1634.	0.6	29
100	Etanercept for the treatment of psoriasis. <i>Expert Review of Dermatology</i> , 2013, 8, 357-372.	0.3	4
101	Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1304-1310.	1.3	13
102	Juvenile Psoriasis und ihre Behandlungsmöglichkeiten: Konsensus einer europäischen Expertengruppe. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 812-819.	0.4	20
103	Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1374-1382.	1.3	88
104	Calciphylaxis. <i>Dermatologic Clinics</i> , 2008, 26, 557-568.	1.0	56
105	Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. <i>Expert Review of Dermatology</i> , 2008, 3, 657-665.	0.3	44
106	Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. <i>British Journal of Dermatology</i> , 2004, 150, 132-135.	1.4	16
107	Severe resistant subacute prurigo successfully controlled by long-term cyclosporin. <i>Journal of Dermatological Treatment</i> , 2003, 14, 48-50.	1.1	6
108	Mucocutaneous presence of cytomegalovirus associated with human immunodeficiency virus infection: discussion regarding its pathogenetic role. <i>Archives of Dermatology</i> , 2001, 137, 443-8.	1.7	38

#	ARTICLE	IF	CITATIONS
109	Helicobacter pylori and idiopathic chronic urticaria. International Journal of Dermatology, 2000, 39, 446-452.	0.5	54
110	Microscopic polyangiitis. A systemic vasculitis with a positive P-ANCA. British Journal of Dermatology, 1996, 134, 542-547.	1.4	11
111	CRYOGLOBULINEMIA AND CUTANEOUS LEUKOCYTOCLASTIC VASCULITIS WITH HEPATITIS C VIRUS INFECTION. International Journal of Dermatology, 1996, 35, 112-115.	0.5	29
112	PAPULAR-PURPURIC GLOVES-AND-SOCKS SYNDROME. International Journal of Dermatology, 1996, 35, 626-632.	0.5	41
113	Fast and sustained Improvement of Patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy, 0, , .	0.8	1